The earnings call presented a mixed picture with strong growth in key products and an optimistic financial outlook overshadowed by significant operating losses and supply constraints for Onapgo. The company is addressing these challenges while maintaining a focus on future growth opportunities.

Company Guidance

In the third quarter of 2025, Supernus Pharmaceuticals reported robust performance driven by its four growth products—Qelbree, GOCOVRI, Zurzuvae, and Onapgo—accounting for approximately 78% of total revenues. Onapgo net sales surged from $1.6 million in Q2 to $6.8 million in Q3, despite supplier constraints limiting its ability to meet high demand. Collaboration revenue from Zurzuvae reached $20.2 million, showcasing a 150% increase in U.S. sales compared to Q3 2024. Qelbree prescriptions grew by 23%, with net sales up 31% year-over-year, bolstered by a strong back-to-school season. GOCOVRI's net sales rose by 15% from the previous year, reflecting growth in prescriptions and prescriber numbers. Total revenue for Q3 2025 was $192.1 million, marking an increase from $175.7 million in Q3 2024. The company updated its 2025 guidance, expecting total revenue between $685 million and $705 million, and non-GAAP operating earnings ranging from $125 million to $145 million.

Strong Growth Products Performance

Qelbree, GOCOVRI, Zurzuvae, and Onapgo accounted for approximately 78% of total revenues. Qelbree achieved 23% growth in prescriptions and 31% growth in net sales compared to the same period last year.

Onapgo Sales Surge

Onapgo generated net sales of $6.8 million in the third quarter, up from $1.6 million in the second quarter.

Zurzuvae Collaboration Revenue

Collaboration revenue from Zurzuvae was $20.2 million in the third quarter of 2025, with U.S. sales increasing approximately 150% compared to the same period in 2024.

Positive Financial Outlook

Updated full year 2025 financial guidance, increasing expected total revenue to range from $685 million to $705 million, up from the previous range of $670 million to $700 million.

Supernus Pharmaceuticals (SUPN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SUPN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 03, 2026	2025 (Q4)	0.39 / -	0.746	―	―	―
Nov 04, 2025	2025 (Q3)	0.59 / 1.00	1.168	-13.96% (-0.16)	―
Aug 05, 2025	2025 (Q2)	0.47 / 0.91	0.771	17.77% (+0.14)	―
May 06, 2025	2025 (Q1)	0.37 / 0.44	0.46	-4.78% (-0.02)	―
Feb 25, 2025	2024 (Q4)	0.52 / 0.75	0.883	-15.52% (-0.14)	―
Nov 04, 2024	2024 (Q3)	0.44 / 1.17	-0.29	502.76% (+1.46)	―
Aug 06, 2024	2024 (Q2)	0.39 / 0.77	-0.02	3955.00% (+0.79)	―
May 08, 2024	2024 (Q1)	0.38 / 0.46	0.29	58.62% (+0.17)	―
Feb 27, 2024	2023 (Q4)	0.55 / 0.88	0.43	105.35% (+0.45)	―
Nov 08, 2023	2023 (Q3)	<0.01 / -0.29	0.03	-1066.67% (-0.32)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SUPN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 04, 2025	$57.00	$47.11	-17.35%
Aug 05, 2025	$37.53	$42.44	+13.08%
May 06, 2025	$32.43	$30.94	-4.59%
Feb 25, 2025	$32.81	$31.91	-2.74%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Supernus Pharmaceuticals (SUPN) report earnings?

Supernus Pharmaceuticals (SUPN) is schdueled to report earning on Mar 03, 2026, After Close (Confirmed).

What is Supernus Pharmaceuticals (SUPN) earnings time?

Supernus Pharmaceuticals (SUPN) earnings time is at Mar 03, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is SUPN EPS forecast?

SUPN EPS forecast for the fiscal quarter 2025 (Q4) is 0.39.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing